The medicine is out of stock

This medicine, discontinued out of stock recently, there are netizens in the People's Daily health client "to see a doctor drug complaint message board" message said, "gallbladderitis commonly used drug pyridodic tablets in Hainan can not buy."
" According to the Health Times, the Hainan Provincial Drug Administration sent a letter in response to the above situation, said that through the Hainan Province pharmaceutical wholesale enterprises, retail chain headquarters to understand that they are not operating a "qupibu tong tablets", one of the main reasons for the shortage of drugs is the supply of raw materials.
patients with chronic gallbladderitis said that the previous box of 50 pieces of cymbals, 22 yuan can be bought, cheap and treatment effect is good.
do not know why, this year, whether in the hospital or pharmacy, can no longer buy this medicine.
the State Drug Administration of China, there are 85 approvals for qumpibutong tablet products, involving a number of pharmaceutical manufacturers.
According to the Hainan Provincial Drug Administration response, Hainan Province medical institutions to purchase the drug network pharmaceutical production enterprises a total of 3 are foreign production enterprises, through the three production enterprises to understand the situation, of which 2 due to raw material supply problems have not yet produced, 1 because of sales problems are not currently sold to the Hainan market this medicine.
Health Times reported that the reporter had called a number of pharmaceutical companies on November 13, staff have said that in recent years have not produced the drug, before the Drug Administration approved are a few years ago.
a pharmaceutical company said there was little API for the production of the tablets.
fact, the qumpibutong film is out of stock in Hainan, in fact, there is a seed.
Cypress blue combing found that as early as April this year, Hainan Province Public Resources Trading Service Center issued "on the public part of the new hanging and withdrawal of the network of drug information notice", the notice mentioned, Qupibutong tablets, lithium carbonate tablets, heparin sodium injection, hydrochloric acid Bubika injection 5 drugs due to rising costs, apply for removal of the net.
, Hainan Province, the central procurement center also issued a notice that 250 drug applications to cancel the network.
Of these 250 drugs, 171 were discontinued due to rising production costs, inability to supply normally, line modifications, production line stoppages, etc., 28 were discontinued due to price increases or shortages of API, and 15 were discontinued due to the inverted bid price and cost.
the reasons for the shortage of qumpibuts mentioned above, it can be seen that many drugs that do not guarantee normal supply are mostly discontinued due to price increases or shortages of API.
the impact of unreasonable price increases of raw materials to the price of raw materials, we should have a deep feeling.
in recent years, the price of some RAW drugs has risen by an astonishing amount.
For example, in 2019, the State Administration of Market Supervision received reports that pharmaceutical distributors had a monopoly on injecting calcium glucosate, resulting in a shortage of calcium glucosate injections and a sharp rise in prices.
2017 sales of calcium glucosate raw materials increased 19 times to 54.6 times compared to 2014 prices.
earlier, Malay acid chlorobenamine rose 58-fold from 400 yuan/kg to 23,300 yuan/kg in a month, and phenol rose 99-fold from 230 yuan/kg to 23,000 yuan/kg.
many of the drugs affected by the rise in the price of API actually have obvious characteristics.
e.g. plate blue root particles, is anti-flu Chinese medicine, the flu season demand is huge
media reported that the secondsodium propylene injection as the only life-saving drug for patients with liver bean-like nuclear degeneration, there has also been a shortage this year.
, according to an August 21 report in the Health Times, the drug has been discontinued for several months and has been in short supply since it was out of stock in March.
it is understood that the shortage of the drug is also due to the problem of raw materials - raw materials factory environmental relocation and process improvement, but the deeper reason is that the market sales are small, enterprises difficult to profit.
price also rose from the previous 29 yuan to 49.5 yuan, and then because of the shutdown rose to 58 yuan, and even was scrambled to 100 yuan.
many cheap life-saving drugs, rare disease drugs are in short supply, mainly because companies do not have enough profit margins, so it will lead to two situations, either price increases to maintain production, or stop loss.
, the state has long attached importance to the issue of the price and cost of medicines.
Previously, the State Health Insurance Administration issued a "notice on doing a good job in the management of drug prices at this stage", in terms of price control mentioned: relying on the provincial drug centralized procurement, the construction of the national drug public procurement market, unified coding, standards and functional norms, promote information connectivity, resource sharing, policy linkage, comprehensive use of monitoring and early warning, correspondence interviews, cost investigation, credit evaluation, information disclosure and other means, and gradually improve specific methods and methods to establish a sound drug price normal supervision mechanism.
In terms of supply security, as early as June 2017, the former State Health and Planning Commission and other nine departments jointly issued "on the reform and improvement of the implementation of the shortage of drug supply guarantee mechanism" put forward, the establishment of a shortage of drug supply security hierarchical linkage response mechanism, the implementation of the shortage of drug supply security classification and precise implementation of the policy.
the era of big data and information technology, drug prices and costs can be effectively avoided.
To solve the shortage of cheap life-saving drugs, if we can start from the root cause, balance the relationship between corporate profits and clinical needs, in the appropriate price range so that enterprises do not lose money, will be able to further protect the vast number of patients daily medication.